<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166992">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923715</url>
  </required_header>
  <id_info>
    <org_study_id>H-24391</org_study_id>
    <secondary_id>R01DK077166-01</secondary_id>
    <nct_id>NCT00923715</nct_id>
  </id_info>
  <brief_title>Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia</brief_title>
  <official_title>Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether exenatide and pramlintide will improve
      blood glucose control after meals when compared to insulin alone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the effect of exenatide vs. pramlintide adjunctive therapy in addition to insulin on glycemic control in T1DM as compared to mono-therapy of insulin.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insulin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin and Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin and Pramlintide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Dose will be as per usual home regimen.</description>
    <arm_group_label>Insulin only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin and Exenatide</intervention_name>
    <description>Exenatide 1.25 up to 2.5 mcg will be given before breakfast and before supper</description>
    <arm_group_label>Insulin and Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin and Pramlintide</intervention_name>
    <description>Pramlintide 15 to 45 mcg will be given before breakfast and supper</description>
    <arm_group_label>Insulin and Pramlintide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 12 to 21 years.

          2. HbA1C less than 9%

          3. Subjects must be on intensive insulin management

          4. C-peptide less than 0.3 ng/ml

          5. Tanner stage greater than or equal to 3

          6. Having T1DM for at least one year

          7. T1DM defined by ADA criteria and having at least one of the following antibodies a.
             Anti-GAD (glutamic acid decarboxylase) b. Anti-islet cell 512 (ICA512) c.
             Anti-insulin

          8. Willing to give consent.

        Exclusion Criteria:

          1. Type 2 diabetes.

          2. Having any other chronic condition except hypothyroidism stable on medications.

          3. On chronic medications that may affect glucose excursions.

          4. Anemia as defined as Hb less than 9 gm/dl.

          5. Abnormal AST, ALT, amylase, lipase or creatinine (twice normal).

          6. Unsupportive family environment as determined by clinicians and/or social workers.

          7. Pregnant or lactating mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubina A Heptulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center CRC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 7, 2010</lastchanged_date>
  <firstreceived_date>June 16, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Rubina A. Heptulla, MD</name_title>
    <organization>Albert Einstein College of Medicine</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Pramlintide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
